Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes

NCT04964024 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT04964024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes
Lead sponsor
Central Hospital, Nancy, France
Phase
Observational
Overall status
Completed
Start date
July 15, 2021
Completion date
May 15, 2022
Enrollment
1,293 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection